LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 ...
“AMPK is a compelling pharmaceutical target and we are encouraged by the outcome of this study. Not only does the data further demonstrate the potential for PXL770 in NASH, the positive effects on DNL ...
Globally ~40% of type 2 diabetes (T2D) patients develop diabetic kidney disease (DKD), and diabetes is the leading cause of end stage renal disease, requiring dialysis or a kidney transplant. Standard ...
Nowadays, the prevalence of sedentary lifestyles and high-caloric diets leads to an imbalance between energy intake and spending. Hence, in the last decades, we have observed a significant rise in ...
STOCKHOLM, Nov. 2, 2017 /PRNewswire/ -- O304 reduces significantly fasting plasma glucose (FPG) in type 2 diabetics The main study results are not yet finalized. Review of the initial data showed that ...
Our findings demonstrate that SOX9 overexpression alleviates hepatic lipid accumulation in MASH by activating the AMPK pathway. These results highlight SOX9 as a promising therapeutic target for ...
AMP-activated protein kinase (AMPK) plays a central role in maintaining energy balance in cells, especially under energy stress. While upstream activation by the kinase LKB1 is well recognized, the ...
The transcription factor sex-determining region Y-related high-mobility group-box gene 9 (SOX9) plays a critical role in organ development. Although SOX9 has been implicated in regulating lipid ...
Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback